SHIFT Newsroom · EU
Foundayo receives European recommendation; EU decision pending
Catch-up: opinion adopted 15 October and published by EMA on 16 October 2026.
The European Medicines Agency's human medicines committee recommended an EU marketing authorisation for Foundayo (orforglipron) on 15 October. The oral GLP-1 medicine was recommended for adult weight management and type 2 diabetes. EMA published the opinion on 16 October.
The European Commission's authorisation decision remained pending on the checked EMA page. A committee recommendation is a separate step from authorisation, commercial launch and reimbursement.
SHIFT’s take
This European development does not itself change UK prescribing eligibility, NHS funding or pharmacy stock. Those require separate UK evidence.
For the separate UK position, including authorisation, evidence and what remains unconfirmed about availability, see our Foundayo UK evidence and availability guide.
Known facts
- The CHMP adopted its positive opinion on 15 October 2026.